Pamiscell is trading at 18,650 KRW as of 9:30 AM on the 24th, up 0.54% from the previous day. This represents a 22.61% decline compared to May 29. Pamiscell is known as a bio-pharmaceutical company that developed the world's first stem cell therapy.

Over the past five days, individual investors have net sold 231,096 shares, while foreigners and institutions have net bought 324,234 shares and net sold 47,871 shares, respectively.

On June 22, Pamiscell was a market topic for its "strength due to Remdesivir administration recommendation."

※Source: AI Investment Assistant AI Racciro

※ This article was generated in real-time by an automatic article generation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.




This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing